CA3223100A1 - Systeme de distribution d'ionophore chimique a membrane cellulaire synthetique comprenant des compositions de ligand hexa-eau - Google Patents

Systeme de distribution d'ionophore chimique a membrane cellulaire synthetique comprenant des compositions de ligand hexa-eau Download PDF

Info

Publication number
CA3223100A1
CA3223100A1 CA3223100A CA3223100A CA3223100A1 CA 3223100 A1 CA3223100 A1 CA 3223100A1 CA 3223100 A CA3223100 A CA 3223100A CA 3223100 A CA3223100 A CA 3223100A CA 3223100 A1 CA3223100 A1 CA 3223100A1
Authority
CA
Canada
Prior art keywords
composition
metal
aqua
hexa
equal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3223100A
Other languages
English (en)
Inventor
Kevin Walton Rude
Michael Kenneth Krysiak
Jasen Eric Petersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionic Alliance Holdings LLC
Original Assignee
Ionic Alliance Holdings LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/390,743 external-priority patent/US20220226371A1/en
Application filed by Ionic Alliance Holdings LLC filed Critical Ionic Alliance Holdings LLC
Publication of CA3223100A1 publication Critical patent/CA3223100A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne des ionophores synthétiques pour l'acheminement et le transport actifs d'ions libres à travers des membranes biologiques in vivo, comprenant des complexes de coordination de molécules avec des systèmes hexa-eau et/ou tétra-eau polarisés de métaux ioniques libres et de sels ioniques en tant qu'ionophores, utiles dans le transport de composés pharmaceutiques, nutritifs et de soins de santé personnels. L'invention concerne également des procédés d'administration de ceux-ci, des procédés de synthèse et de fabrication de ceux-ci, et les produits ionophores issus de tels procédés de synthèse et de fabrication.
CA3223100A 2021-06-16 2022-05-23 Systeme de distribution d'ionophore chimique a membrane cellulaire synthetique comprenant des compositions de ligand hexa-eau Pending CA3223100A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202117349880A 2021-06-16 2021-06-16
US17/349,880 2021-06-16
US17/390,743 US20220226371A1 (en) 2021-01-13 2021-07-30 Synthetic Cellular Membrane Chemical Ionophore Delivery System Comprising Hexa-Aqua Ligand Compositions
US17/390,743 2021-07-30
PCT/US2022/030607 WO2022265829A1 (fr) 2021-06-16 2022-05-23 Système de distribution d'ionophore chimique à membrane cellulaire synthétique comprenant des compositions de ligand hexa-eau

Publications (1)

Publication Number Publication Date
CA3223100A1 true CA3223100A1 (fr) 2022-12-22

Family

ID=84527605

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3223100A Pending CA3223100A1 (fr) 2021-06-16 2022-05-23 Systeme de distribution d'ionophore chimique a membrane cellulaire synthetique comprenant des compositions de ligand hexa-eau

Country Status (5)

Country Link
AU (1) AU2022291691A1 (fr)
CA (1) CA3223100A1 (fr)
DE (1) DE112022002702T5 (fr)
GB (1) GB2622558A (fr)
WO (1) WO2022265829A1 (fr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753031A (en) * 1996-09-27 1998-05-19 W. R. Grace & Co.-Conn. Composition and method to remove asbestos
GB9929255D0 (en) * 1999-12-11 2000-02-02 British Nuclear Fuels Plc Compound
FR2843752B1 (fr) * 2002-08-26 2007-05-18 Pancosma Sa Pour L Ind Des Pro Oligo-elements cristallins, et procedes pour leur fabrication
JP4185311B2 (ja) * 2002-05-10 2008-11-26 新興化学工業株式会社 バナジウムレドックスフロー電池電解液用固形組成物
WO2015122250A1 (fr) * 2014-02-17 2015-08-20 三菱瓦斯化学株式会社 Composition liquide de gravure d'oxydes comprenant l'indium, le zinc, l'étain et de l'oxygène, et procédé de gravure
CA3080157A1 (fr) * 2017-10-26 2019-05-02 Array Biopharma Inc. Formulations d'un inhibiteur de kinase trk macrocyclique
IN201813025436A (fr) * 2018-07-07 2020-01-10 Balendu Prakash Vaidya

Also Published As

Publication number Publication date
GB2622558A (en) 2024-03-20
GB202400617D0 (en) 2024-02-28
DE112022002702T5 (de) 2024-04-18
WO2022265829A1 (fr) 2022-12-22
AU2022291691A1 (en) 2024-02-01

Similar Documents

Publication Publication Date Title
US11638721B2 (en) Antibacterial composition and its use in treating bacterial infections
ES2397657T3 (es) Preparación de combinación para mejorar la calidad del esperma
KR102247982B1 (ko) 항종양 알칼로이드를 이용한 병용요법
AU2004204778A1 (en) Treatment of cancer with 2-deoxyglucose
US20060008908A1 (en) Method and composition for longevity assurance
WO2008100418A1 (fr) Complexes de zinc d'acides aminés naturels pour le traitement de toxicités provoquées par un cuivre élevé
JP2004530659A (ja) 抗腫瘍および抗転移作用のための方法および処方
CN102046180A (zh) 用于免疫治疗的组合物和方法
KR101100786B1 (ko) 암에 대한 방사선 치료 증진용 조성물
MXPA02002211A (es) Metodo y formula para la remision de tumores y supresion de cancer.
US20220226371A1 (en) Synthetic Cellular Membrane Chemical Ionophore Delivery System Comprising Hexa-Aqua Ligand Compositions
CA3223100A1 (fr) Systeme de distribution d'ionophore chimique a membrane cellulaire synthetique comprenant des compositions de ligand hexa-eau
Chiaverini et al. AS101: An overview on a leading tellurium-based prodrug
WO2008151520A1 (fr) Utilisation de sélénosulfate de sodium pour complémenter le sélénium et améliorer l'efficacité de traitement d'agents de chimiothérapie, et son procédé de préparation rapide
Mei Review of the toxicological mechanism of anticancer drug cisplatin
JP4707668B2 (ja) オキソプラチン、その塩および誘導体を含む医薬組成物
WO2009091291A1 (fr) Sel d'argent de n-(6-méthyl-2,4-dioxo-1,2,3,4-tétrahydro-5h-pyrimidinesulfone)-isonicotinoyl hydrazide
CN109550053A (zh) 一种双药配位聚合物抗结核纳米药物的制备方法
ES2891773T3 (es) Composición inyectable que comprende un complejo de dextrano de hierro y vitaminas para prevenir y tratar la anemia
US20170071887A1 (en) Method for applying metformin and sodium butyrate in k-ras mutation cancer treatment
JP5771316B2 (ja) 前立腺癌細胞の放射線抵抗性の低減、および／または前立腺癌の治療のための医薬組成物
US20050220899A1 (en) Use of cisplatin in combination with folic acid for increasing cisplatin efficacy
EP2068894B1 (fr) Utilisation de composés de diadamantate de rhénium cis (iii) pour potentialiser l'activité antitumorale des complexes de platine.
WO2005065695A1 (fr) Methode et formule de suppression de cancer, de metastase, de vascularisation et de soulagement de douleurs
US20080233207A1 (en) Injectable and Infusable Mercury Compositions and Methods for Treating Cancer